DALLAS--(BUSINESS WIRE)--
Jacobs
Engineering Group Inc. (NYSE:JEC) has received an engineering,
procurement and construction management (EPCM) contract from Pfizer
Inc. for a new gene therapy manufacturing facility located at the
company’s manufacturing site in Sanford, North Carolina. Under the terms
of the contract, Jacobs will perform all required services to design,
build and qualify the multi-product facility, which will manufacture
gene therapy products upon completion. In addition to EPCM, Jacobs will
provide design, expediting and commissioning services for the project.
Gene therapy is an emerging area of medical research focused on highly
specialized, one-time, transformative treatments addressing the root
cause of diseases caused by genetic mutation.
“As a leader in gene therapy EPCM projects, Jacobs delivers end-to-end
solutions in support of gene therapy research and advancement,” said Jacobs
Life Sciences, Consumer Goods and Manufacturing Senior Vice President
and General Manager Ken Gilmartin. “Working on this project, we envision
a day in the future when these potentially transformative gene therapies
become available to treat medical conditions to help people enjoy
healthier lives.”
Jacobs leads the global professional services sector delivering
solutions for a more connected, sustainable world. With $15 billion in
combined revenue and a talent force more than 74,000 strong, Jacobs
provides a full spectrum of services including scientific, technical,
professional and construction- and program-management for business,
industrial, commercial, government and infrastructure sectors. For more
information, visit www.jacobs.com.
Statements made in this release that are not based on historical fact
are forward-looking statements. We base these forward-looking statements
on management’s current estimates and expectations as well as currently
available competitive, financial and economic data. Forward-looking
statements, however, are inherently uncertain. There are a variety of
factors that could cause business results to differ materially from our
forward-looking statements. For a description of some of the factors
which may occur that could cause actual results to differ from our
forward-looking statements please refer to our Form 10-K for the year
ended September 29, 2017, and in particular the discussions contained
under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and
7 - Management's Discussion and Analysis of Financial Condition and
Results of Operations. We do not undertake to update any forward-looking
statements made herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005133/en/
Source: Jacobs Engineering Group Inc.